مباشر
Endpoints News#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetesClinical OMICsBlood-Based Risk Score Could Enable Earlier Lung Cancer PreventionClinical OMICsMicroglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to DementiaEndpoints NewsIn Washington, biotech's China hawks are winning the conversationClinical OMICsUniversal Coronavirus Vaccine Could Provide Protection Against Future StrainsEndpoints NewsIndustry seeks more clarity on commissioner's voucher programBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 4, 2026BioWorldBioWorld and Nasdaq stock indicesEndpoints NewsHouse committee directs FDA to speed up IND sign-off processFierceBiotechExecutive Interviews at Fierce Biotech Week 2026BioWorldBiopharma money raised by month in 2026 (US$M)
10x Genomics Blog ١٣ يناير ٢٠٢٦

Weak Instrument Sales And No 2026 Outlook Could Be A Game Changer For 10x Genomics (TXG) - Yahoo Finance

Weak Instrument Sales And No 2026 Outlook Could Be A Game Changer For 10x Genomics (TXG) - Yahoo Finance

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.